Sage Therapeutics (SAGE) PT Raised to $105 at Cowen Following WATERFALL Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq lags peers as Netflix, chip stocks drag; AmEx lifts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Jabil falls after placing CEO on paid leave amid internal investigation
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Guggenheim Downgrades Sage Therapeutics (SAGE) to Neutral, Following Clinical Business Update
June 15, 2021 11:49 AM EDTGuggenheim analyst Yatin Suneja downgraded Sage Therapeutics (NASDAQ: SAGE) from Buy to Neutral.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $72.86 yesterday.
... MoreBiogen (BIIB) PT Raised to $415 at BofA Securities After Waterfall Data Despite Modest Treatment Effect
June 15, 2021 10:22 AM EDTBofA Securities analyst Geoff Meacham raised the price target on Biogen (NASDAQ: BIIB) to $415.00 (from $400.00) while maintaining a Neutral rating after SAGE Therapeutics (NASDAQ: SAGE) reported that WATERFALL, its phase 3 of zuranolone for major depressive disorder (MDD), met the... More
Sage Therapeutics (SAGE) Top Line WATERFALL Data Shows Stat Sig Benefit at Day 15 - Mizuho
June 15, 2021 10:10 AM EDTMizuho Securities analyst Vamil Divan reiterated a Buy rating and $160.00 price target on Sage Therapeutics (NASDAQ: SAGE) after the company released topline data for their much-anticipated WATERFALL study for zuranolone in major depressive disorder.
The analyst stated "The results are technically positive as... More
Sage Therapeutics (SAGE), Biogen (BIIB) Phase 3 for Zuranolone for Major Depressive Disorder Shows Statistically Significant Improvement
June 15, 2021 6:31 AM EDT(Updated - June 15, 2021 6:32 AM EDT)
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the WATERFALL Study in patients with MDD met its primary endpoint with zuranolone (SAGE-217/BIIB125) 50 mg showing statistically significant improvement in depressive symptoms compared with placebo at Day 15 as assessed by the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score. LS means (SE) change from baseline in HAMD-17 total score at Day 15 for patients who received zuranolone 50 mg was -14.1 (0.51) compared with -12.3 (0.50) for patients who received placebo (LS mean... More
